首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1685160

胃腸道糞便檢測市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測

GI Stool Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年01月06日 | 出版商:

Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球胃腸道糞便檢測市場規模達到 6.502 億美元，預計 2025 年至 2034 年期間的複合年成長率為 7.8%。胃腸道疾病盛行率的不斷上升、預防保健意識的不斷增強以及診斷技術的不斷進步是推動這一成長的主要因素。隨著消化健康受到越來越多的關注，醫療保健提供者正在積極將非侵入性且有效的糞便檢測方法納入常規篩檢中。糞便診斷工具的準確性、可負擔性和可近性的提高進一步支持了這種廣泛的應用，使其成為早期疾病檢測不可或缺的一部分。

消費者越來越重視主動醫療保健，從而推動了對能夠提供可靠結果且不適感最小的基於糞便的診斷的需求。向家庭檢測解決方案的轉變也促進了市場擴張，使個人可以方便地進行篩檢，而無需頻繁去醫院。此外，政府推動的大腸直腸癌篩檢計畫和醫療環境中的感染控制措施的措施正在創造有利的監管環境。市場也受益於全球醫療保健基礎設施的不斷擴張，確保了更廣泛地獲得先進的診斷解決方案。隨著研發力度的加快，人工智慧驅動的分析和基於生物標記的糞便測試等新興技術正在提高診斷的準確性，進一步加強市場的成長軌跡。

市場範圍
起始年份	2024
預測年份	2025-2034
起始值	6.502 億美元
預測值	14億美元
複合年成長率	7.8％

2024 年消耗品部分的價值為 4.047 億美元，涵蓋試劑、檢測試劑盒和樣本採集工具等基本診斷組件。這些物品在確保測試準確且有效率方面發揮著至關重要的作用，因此實驗室和醫療機構對它們的需求一直很強烈。一次性消耗品因其能有效降低污染風險並維持嚴格的感染控制標準而越來越受歡迎。隨著醫療保健提供者繼續優先考慮精確度和可靠性，對高品質診斷用品的依賴預計會增加。不斷擴大的分銷網路也改善了這些基本部件的獲取，促進了無縫診斷程序。

在各種測試類型中，潛血測試佔據市場領先地位，預計到 2034 年將達到 7.126 億美元，複合年成長率為 8.7%。這些檢查對於早期發現大腸直腸癌和胃腸道出血至關重要，可顯著改善診斷和治療結果。它們能夠識別糞便樣本中隱藏的血跡，這使它們成為國家篩檢計畫的重要組成部分。潛血檢測的經濟性和非侵入性鼓勵了更多患者參與，支持早期疾病介入。隨著醫療保健提供者強調主動疾病管理，對這些測試的需求持續上升。

2024 年，美國胃腸道糞便檢測市場價值為 2.737 億美元，預計到 2034 年複合年成長率為 7.3%。該國先進的醫療保健基礎設施和對預防保健的高度重視是推動市場擴張的關鍵因素。大腸直腸癌篩檢的保險覆蓋範圍的擴大加速了糞便檢測解決方案的採用，強調了早期疾病檢測的重要性。隨著診斷工具的不斷進步和對個人化醫療的日益重視，美國市場有望實現持續成長，並透過創新且易於獲取的檢測解決方案確保改善患者的治療效果。

產業生態系統分析
產業衝擊力
- 成長動力
  - 胃腸道疾病盛行率上升
  - 糞便檢測儀器的技術進步
  - 家庭糞便檢測試劑盒的普及率不斷提高
  - 對胃腸道疾病早期診斷和預防的需求日益成長
- 產業陷阱與挑戰
  - 缺乏熟練的專業人員
  - 嚴格的監理政策
成長潛力分析
2024 年定價分析
報銷場景
監管格局
技術格局
差距分析
波特的分析
PESTEL 分析
未來市場趨勢
價值鏈分析

第4章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
主要市場參與者的競爭分析
競爭定位矩陣
策略儀表板

第 5 章：市場估計與預測：按產品類型，2021 年至 2034 年

主要趨勢
耗材
分析器

第 6 章：市場估計與預測：按測試類型，2021 年至 2034 年

主要趨勢
潛血檢查
- 免疫FOB凝集試驗
- 免疫 FOB ELISA 檢測
- 橫向流動免疫FOB檢測
- 癒創木脂 FOB 糞便測試
細菌檢測
糞便生物標記檢測
- 腫瘤M2-PK糞便檢測
- 轉鐵蛋白檢測
- 其他糞便生物標記測試
蟲卵及寄生蟲檢測
其他測試類型

第 7 章：市場估計與預測：按應用，2021 年至 2034 年

主要趨勢
感染
癌症
發炎性腸道疾病
胃食道逆流症（GERD）
其他應用

第 8 章：市場估計與預測：按配銷通路，2021 年至 2034 年

主要趨勢
實體店面
電子商務

第 9 章：市場估計與預測：依最終用途，2021 年至 2034 年

主要趨勢
醫院和診所
診斷中心
家庭護理設置
其他最終用戶

第 10 章：市場估計與預測：按地區，2021 年至 2034 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第 11 章：公司簡介

Abbott Laboratories
danaher
BIO RAD
BIOMRIEUX
CardinalHealth
Cenogenics
CTK BIOTECH
Diasorin
EDI
GENOVA DIAGNOSTICS
meridian BIOSCIENCE
Quest Diagnostics
ScheBo Biotech
SIEMENS

簡介目錄

Product Code: 5719

The Global GI Stool Testing Market reached USD 650.2 million in 2024 and is projected to expand at a CAGR of 7.8% between 2025 and 2034. The increasing prevalence of gastrointestinal disorders, rising awareness of preventive healthcare, and ongoing advancements in diagnostic technologies are key drivers behind this growth. As digestive health gains more attention, healthcare providers are actively incorporating non-invasive and efficient stool testing methods into routine screenings. This widespread adoption is further supported by the enhanced accuracy, affordability, and accessibility of stool-based diagnostic tools, making them an integral part of early disease detection.

Consumers are increasingly prioritizing proactive healthcare, fueling demand for stool-based diagnostics that provide reliable results with minimal discomfort. The shift towards home-based testing solutions is also contributing to market expansion, allowing individuals to conduct screenings conveniently without frequent hospital visits. Additionally, government initiatives promoting colorectal cancer screening programs and infection control measures in medical environments are creating a favorable regulatory landscape. The market is also benefiting from the continuous expansion of healthcare infrastructure worldwide, ensuring broader accessibility to advanced diagnostic solutions. As research and development efforts accelerate, emerging technologies such as AI-driven analysis and biomarker-based stool tests are enhancing diagnostic accuracy, further strengthening the market's growth trajectory.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$650.2 Million
Forecast Value	$1.4 Billion
CAGR	7.8%

The consumables segment accounted for USD 404.7 million in 2024, encompassing essential diagnostic components such as reagents, test kits, and sample collection tools. These items play a crucial role in ensuring accurate and efficient testing, leading to their consistent demand across laboratories and healthcare facilities. Single-use consumables are becoming increasingly popular due to their effectiveness in reducing contamination risks and maintaining strict infection control standards. As healthcare providers continue prioritizing precision and reliability, the reliance on high-quality diagnostic supplies is expected to grow. Expanding distribution networks are also improving access to these essential components, facilitating seamless diagnostic procedures.

Among various test types, occult blood tests are leading the market, with projections to reach USD 712.6 million by 2034 at a CAGR of 8.7%. These tests are essential for detecting colorectal cancer and gastrointestinal bleeding at an early stage, significantly improving diagnosis and treatment outcomes. Their ability to identify hidden traces of blood in stool samples makes them a critical component of national screening programs. The affordability and non-invasive nature of occult blood tests encourage higher patient participation, supporting early disease intervention. As healthcare providers emphasize proactive disease management, demand for these tests continues to rise.

U.S. GI stool testing market was valued at USD 273.7 million in 2024 and is projected to grow at a CAGR of 7.3% through 2034. The country's advanced healthcare infrastructure and strong focus on preventive care are key factors driving market expansion. Increased insurance coverage for colorectal cancer screenings has accelerated the adoption of stool testing solutions, reinforcing the importance of early disease detection. With continuous advancements in diagnostic tools and a growing emphasis on personalized medicine, the U.S. market is poised for sustained growth, ensuring improved patient outcomes through innovative and accessible testing solutions.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in prevalence of gastrointestinal disorders
  - 3.2.1.2 Technological advancements in stool testing instruments
  - 3.2.1.3 Increasing adoption of at-home stool testing kits
  - 3.2.1.4 Growing demand for early diagnosis and prevention of GI diseases
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Lack of skilled professionals
  - 3.2.2.2 Stringent regulatory policies
3.3 Growth potential analysis
3.4 Pricing analysis, 2024
3.5 Reimbursement scenario
3.6 Regulatory landscape
3.7 Technology landscape
3.8 Gap analysis
3.9 Porter's analysis
3.10 PESTEL analysis
3.11 Future market trends
3.12 Value chain analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

5.1 Key trends
5.2 Consumables
5.3 Analyzers

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 – 2034 ($ Mn)

6.1 Key trends
6.2 Occult blood test
- 6.2.1 Immuno FOB agglutination test
- 6.2.2 Immuno FOB ELISA test
- 6.2.3 Lateral flow immuno FOB test
- 6.2.4 Guaiac FOB stool test
6.3 Bacteria test
6.4 Fecal biomarkers test
- 6.4.1 Tumor M2-PK stool test
- 6.4.2 Transferrin assays
- 6.4.3 Other fecal biomarkers tests
6.5 Ova and parasites test
6.6 Other test types

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

7.1 Key trends
7.2 Infection
7.3 Cancer
7.4 Inflammatory bowel disease
7.5 Gastroesophageal reflux disease (GERD)
7.6 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

8.1 Key trends
8.2 Brick and mortar
8.3 E-commerce

Chapter 9 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

9.1 Key trends
9.2 Hospitals and clinics
9.3 Diagnostic centers
9.4 Homecare settings
9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE